Aesthetics Tech Forum 2027

Rapalogix Health (Judge’s Choice)

Rapalogix was recognized for its science-driven approach to restoring cellular balance as a foundation for lifelong skin health. Judges highlighted its focus on durability, mechanism of action, and translational relevance. The platform reads as a long-term play aligned with clinical credibility and regulatory rigor.

Tempo Therapeutics (People’s Choice)

Tempo resonated for its ambitious vision of building functional tissue and organs in vivo alongside next-generation, shelf-stable vaccine technologies. The breadth and scientific depth stood out to an audience drawn to biology-led, transformational platforms. Interest centered on long-term potential rather than near-term quick wins.

Access to the Industry Elite: The Aesthetics Tech Forum brings together top physicians, entrepreneurs, and investors in the field. This is your chance to make connections and receive feedback from the industry’s most influential players.
Visibility and Credibility: Pitching at our Forum not only puts your company in the spotlight but also boosts your credibility. Gain recognition from peers, investors, and potential partners.
Mentorship and Resources: Selected companies will have the opportunity to meet with Octane’s Capital Assist & LaunchPad SBDC Accelerator teams, offering mentorship, resources, and a clear path to growth.

AiViva is a clinical-stage biopharma company developing therapies for ophthalmology and dermatology diseases. AIV001 is a multi-target kinase inhibitor showing first-in-class clinical effects in non-melanoma skin cancer and scar modulation, enabling tumor clearance without disfiguring surgery and unprecedented scar resolution, including in difficult scars. AIV007 is a periocular drug depot for retinal disorders such as nAMD, achieving target engagement with a demonstrated twice-yearly dosing schedule and rapid improvements in macular edema and visual acuity. With strong composition-of-matter IP and clear clinical and partnering inflection points, AiViva offers a compelling investment opportunity.

Aurris AI is the first native AI platform purpose-built for the $500B medical aesthetics industry, solving its most pressing challenge—patient conversion. Founded by industry insiders and seasoned tech disruptors, Aurris AI combines deep domain expertise with cutting-edge technology to help brands and practices turn patient interest into action. Free from FDA regulatory constraints, our HIPAA-compliant platform deploys rapidly, enabling fast go-to-market scalability. With multiple revenue streams—including a SaaS subscription for practices and brands, and a per-transaction broker fee for patient financing—Aurris delivers immediate value while building a defensible, high-growth business in one of healthcare’s fastest-growing segments.

Founded on Breakthrough mRNA Research

BEMY is a science-driven and technology-empowered cosmeceuticals company headquartered in Houston, Texas. The company, founded by PhD-level scientists and entrepreneurs with significant expertise in the design and application of cosmetic and pharmaceutical products, specializes in small molecules and messenger RNA (mRNA), as well as proprietary cosmetic base formulations. Enabled by patented technology, our scientists have engineered a new and highly innovative platform in skin rejuvenation.

Etienna Bio is transforming the future of beauty by using your own living cells to restore natural volume, smoothness, and youthful glow—without synthetic fillers or repeated injections. From a sample smaller than a gram of fat, our breakthrough technology grows healthy new tissue that looks and feels completely natural. It’s your body, rejuvenated—long-lasting, biocompatible, and tailored just for you. Backed by top scientific research, Etienna’s approach brings the power of biotech regenerative medicine into the world of aesthetics, offering a truly personalized, “living beauty” solution that lasts.

GetHairMD is a national network of more than 70 physician-led practices focused on solving every stage and cause of hair loss. Built on a combination-therapy, science-backed approach, GetHairMD delivers comprehensive solutions that include personalized DNA insights, prescription protocols, at-home regimens, laser technology, stress and lifestyle support, and in-clinic non-invasive treatments.

The company partners exclusively with medical practices, providing proprietary technologies, protected territories, and a suite of simplified, scalable offerings that elevate patient outcomes and drive long-term practice growth. As the category leader advancing innovation in hair restoration, GetHairMD brings a curated clinical technology stack directly to providers and patients.

Through trusted partnership, proven expertise, and results-driven care, GetHairMD helps practices strengthen their businesses and empowers patients to regain confidence and quality of life.

ProTransit is commercializing a sustained-release microparticle platform that delivers actives better, faster, and safer than needles and pills. Pro-MP TM , when applied topically may achieve higher concentrations than oral dosing while reducing side effects. Pro-MP is proven to improve health and appearance of sun-damaged skin using SOD-CAT antioxidants and promotes hair regrowth with topical finasteride. Pro-MP SOD-CAT is protected by trade secrets and patented through 2035 (US) and 2042 (Canada).

Patents are pending for other activities. R& is assessing encapsulation of newer actives for acne, dynamic wrinkles, and skin volumizing. Pro-Transit is seeking visionary investors or forward-looking companies to license.

Using MAP technology, we are building functional tissue and organs within patients to treat disease. Our mission is to use MAP technology to harness the power of immunomodulation and material science to transform the landscape of medical technology, enabling the future of medicine.

Tempo’s leading biosurgery products solve significant clinical challenges in patients undergoing soft tissue reconstructions for dermal and abdominal wall indications. By building new vascular tissue in these patients, our products improve tissue strength and restore function – improving outcomes and saving lives. Using the MAP core technology, Tempo is also developing combination drug delivery, allogenic cell engraftment, and next-generation vaccine technologies.

Tempo is developing novel therapies based on MAP technology in many therapeutic areas. We are actively engaged in building strategic relationships to bolster current development and access new therapeutic areas – with the goal of using tissue engineering to build better lives for patients in need.

TruElastin’s technology and product development platform was designed to unlock the power of natural elastin biomaterials for human health. By harnessing the power of elastin, we have the opportunity to address unmet healthcare needs not only in medical aesthetics, but in a wide range of therapeutic areas. Our flexible approach to producing true elastin biomaterials allows for the creation of functional tissue-engineered products and advanced drug delivery systems.

Elastin is a beautiful, complex, and immensely useful gift from Nature. It’s our goal to make the most of it!

Why You Should Apply to Present at Octane Signature Events: